<SEC-DOCUMENT>0000899243-22-031504.txt : 20220919
<SEC-HEADER>0000899243-22-031504.hdr.sgml : 20220919
<ACCEPTANCE-DATETIME>20220919174440
ACCESSION NUMBER:		0000899243-22-031504
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220915
FILED AS OF DATE:		20220919
DATE AS OF CHANGE:		20220919

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Deshpande Milind
		CENTRAL INDEX KEY:			0001378588

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38266
		FILM NUMBER:		221251501

	MAIL ADDRESS:	
		STREET 1:		ACHILLION PHARMACEUTICALS
		STREET 2:		300 GEORGE STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701108
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-242-1600

	MAIL ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spero Therapeutics, LLC
		DATE OF NAME CHANGE:	20170316
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-09-15</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001701108</issuerCik>
        <issuerName>Spero Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>SPRO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001378588</rptOwnerCik>
            <rptOwnerName>Deshpande Milind</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SPERO THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>675 MASSACHUSETTS AVENUE, 14TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02139</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-09-15</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>15000</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>31454</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Consists of restricted stock units (&quot;RSUs&quot;). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Tamara Joseph, Attorney-in-Fact for Milind Deshpande</signatureName>
        <signatureDate>2022-09-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
